News Releases

Baker Botts Guides Boehringer Ingelheim to FTC Clearance of Historic $13.5 Billion Asset Swap Transaction with Sanofi

News Release
WASHINGTON, December 28, 2016 - Baker Botts L.L.P., a leading international law firm, is pleased to announce that its client Boehringer Ingelheim GmbH, one of the world’s leading pharmaceutical and animal health companies, today obtained antitrust clearance from the U.S. Federal Trade Commission of its asset swap transaction with Sanofi. Through the Boehringer-Sanofi transaction, Boehringer will acquire Sanofi’s global animal health business, Merial, while Sanofi will acquire Boehringer’s global consumer health care business. In terms of asset value, the transaction is the largest deal in the history of both companies. 

As a condition of FTC clearance, the parties will divest certain pet vaccines and a cattle parasitcide product in the United States. No FTC divestitures were required in any consumer health product segments. 

The Baker Botts team was led by Washington DC based partners Stephen Weissman and William Henry and associates Ryan Foley, Christine Ryu, and Matt Adler

For more information, please see the FTC news release by clicking here


# # # 

About Baker Botts LLP
Baker Botts is an international law firm of approximately 725 lawyers practicing throughout a network of 14 offices around the globe. Based on our experience and knowledge of our clients’ industries, we are recognized as a leading firm in the energy and technology sectors. Throughout our 177-year history, we have provided creative and effective legal solutions for our clients while demonstrating an unrelenting commitment to excellence. For more information, please visit

Related Professionals